Did you know that more than half of your patients with type 2 diabetes have NAFLD?
- May 7, 2020
As the prevalence of NAFLD continues to grow and the risk for NASH is significantly increased in patients with type 2 diabetes, it is important to screen all those in whom NASH is a clinically possibility (e.g. elevated ALT, evidence of fatty liver, etc.).
- NAFLD is known as a silent disease.
- Patients often have no symptoms in early stages, but can progress to NASH, one of the major causes of cirrhosis.
- 1 in 2 (50%) T2DM patients have NAFLD, of these up to 4 in 5 (80%) have NASH.
- T2DM patients with NASH are at higher risk of overall morbidity and mortality.
We have created LiverMultiScan to combat the rising burden of fatty liver disease.
LiverMultiScan helps you assess your patients’ liver health. With a quick, non-invasive MRI examination, LiverMultiScan characterizes liver tissue and provides key metrics shown to correlate with histology^ and predict clinical outcomes^.
LiverMultiScan metrics can be used to aid in the diagnosis of liver diseases and help clinicians determine the type of treatment needed.
To learn how LiverMultiScan can help Endocrinologists assess patients’ liver health, download our one-pager today and discover more about:
- NASH therapeutics
- Healthy patient vs. NASH patient
- Enhancing the clinical care of T2DM patients
Interested in using our technology? Call our office at 1.972.803.5501 or email our clinical outreach team:
Madison Wagner, Clinical Solutions Specialist
Prof. Carlos Duncker MD, PhD, Medical Science Liaison